Allyson J. Ocean, Professor of Clinical Medicine at Weill Cornell Medicine, shared a post on LinkedIn:
“The energy heading into ASCO 2026 feels different.
For the first time in years, we are seeing truly practice-changing momentum across GI cancers, especially pancreatic cancer, with advances in RAS targeting, immunotherapy, precision medicine, and novel combinations that once seemed out of reach.
Honored to be quoted in this BioSpace article previewing some of the most anticipated presentations of the meeting, including Revolution Medicines‘ phase 3 RASolute 302 trial and other major GI oncology data shaping the future of cancer care.”
Other articles featuring Allyson J. Ocean on OncoDaily.